Table 3.

Staphylococcus aureus Antigen-Specific Responses in the Evaluable Immunogenicity Population: GMFR From Baseline at Month 36

Antigen	Age Group, y	Placebo	High-Dose SA4Aga
		GMFR (95% CI)	GMFR (95% CI)
CP5b	18–64	1.0 (0.8–1.3)	8.1 (6.0–10.8)
	65–85	0.8 (0.6–0.9)	6.3 (4.0–9.8)
CP8b	18–64	1.0 (0.8–1.2)	4.5 (3.2–6.4)
	65–85	0.8 (0.6–1.0)	4.3 (2.5–7.3)
ClfAc	18–64	1.0 (1.0–1.1)	3.9 (2.8–5.3)
	65–85	1.0 (0.9–1.0)	2.7 (1.8–4.0)
ClfAd	18–64	1.3 (1.0–1.6)	4.4 (3.1–6.3)
	65–85	1.1 (1.0–1.3)	4.0 (2.9–5.4)
rMntCd	18–64	1.0 (0.9–1.3)	1.8 (1.5–2.1)
	65–85	1.3 (1.1–1.5)	1.5 (1.2–1.8)

Abbreviations: CI, confidence interval; ClfA, surface protein clumping factor A; cLIA, competitive Luminex immunoassay; CP5, capsular polysaccharide serotype 5; CP8, capsular polysaccharide serotype 8; FBI, fibrinogen-binding inhibition; GMFR, geometric mean fold rise; OPA, opsonophagocytic activity; rMntC, recombinant manganese transporter protein C; SA4Ag, Staphylococcus aureus 4-antigen vaccine.

^aHigh-dose SA4Ag included CP5-CRM₁₉₇ 30 μg, CP8-CRM₁₉₇ 30 μg, rmClfA 60 μg, and rMntC 200 μg.

^bDetermined via OPA assay.

^cDetermined via FBI assay.

^dDetermined via cLIA.